Nykode Therapeutics AS Ordinary Shares NYKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYKD is a good fit for your portfolio.
News
-
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
-
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
-
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
Trading Information
- Previous Close Price
- NOK 12.90
- Day Range
- NOK 12.82–13.20
- 52-Week Range
- NOK 12.38–30.86
- Bid/Ask
- NOK 12.50 / NOK 13.40
- Market Cap
- NOK 4.24 Bil
- Volume/Avg
- 639,229 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 168
- Website
- https://www.nykode.com
Comparables
Valuation
|
Metric
|
NYKD
|
CGEM
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.43 | 2.39 | 4.31 |
Price/Sales | 28.54 | — | 23.79 |
Price/Cash Flow | — | — | — |
Price/Earnings
NYKD
CGEM
PTGX
Financial Strength
|
Metric
|
NYKD
|
CGEM
|
PTGX
|
|---|---|---|---|
Quick Ratio | 7.91 | 16.60 | 16.54 |
Current Ratio | 8.04 | 17.07 | 16.71 |
Interest Coverage | −235.75 | — | — |
Quick Ratio
NYKD
CGEM
PTGX
Profitability
|
Metric
|
NYKD
|
CGEM
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −19.18% | −24.60% | −16.60% |
Return on Equity (Normalized) | −26.31% | −25.95% | −18.20% |
Return on Invested Capital (Normalized) | −30.96% | −29.67% | −23.45% |
Return on Assets
NYKD
CGEM
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tswqnvtsg | Bblhc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmrtysw | Mbyhsk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pwtjpbww | Dfdxcc | $97.8 Bil | |
MRNA
| Moderna Inc | Rlwktdk | Btrdh | $41.3 Bil | |
ARGX
| argenx SE ADR | Svfmrffv | Khbh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Wjqldhc | Sqhr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Txynsbz | Hhgqg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nqxvgzx | Gfntmx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jhfykdmljk | Hcfbmdn | $12.5 Bil | |
INCY
| Incyte Corp | Dbhxbpqj | Qjhknw | $11.6 Bil |